Clinical TrialsRapid enrollment in the Phase II VENTURE-Oral study of VK2735 suggests significant enthusiasm from clinicians and patients.
Manufacturing AgreementThe newly announced supply agreement is considered a major win for the company and adds value to overall program and partner conversations.
Market PositioningViking Therapeutics has announced a manufacturing agreement with CordenPharma, securing large-scale production capacity for VK2735, which strengthens its market positioning.
Strategic MovesAnalysts reiterate a Buy rating for VKTX, underlining confidence in the company's strategic moves and market potential.